• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

initial public offering

new york stock exchange
Favicon Fierce Pharma

Veradermics locks in $256M IPO, shares spike

With an oversubscribed trading debut now in the books, Veradermics is well coiffed to tap into the growing opportunity for pattern hair loss drugs.
Fraiser Kansteiner Feb 5, 2026 10:01am
IPO initial public offering Wall Street

Big Pharma-backed MapLight plots IPO

Sep 22, 2025 1:57pm
HKEX

Leads Biolabs hits Hong Kong stock exchange in $189M IPO

Jul 25, 2025 10:59am
long road journey highway desert mountains path

Alopexx seeks IPO to advance ex-Sanofi infectious disease drug

Feb 26, 2025 10:04am
illustration of venture capital investment funding

Tempus AI IPO drives $6.6B in VC exit value for medtech sector

Aug 21, 2024 10:21am
brain neurological neurosurgery

Rapport talks up $122M IPO for proof-of-concept epilepsy trials

Jun 3, 2024 7:10am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings